Regenerative Medicine Review: The Clinical Potential of Muse Cells and Exosomes

Scope note

This article deliberately separates generic Muse-cell science from product-specific claims about Dezawa MuseCells® and Dezawa MuseExosomes®. Peer-reviewed studies are used for broader biology and human clinical evidence. Supplied company materials are used where the article discusses licensed manufacturing, product framing, or storage and handling. That distinction protects scientific accuracy.

Key message

Muse cells matter because they may combine adult-derived practicality, injury-responsive delivery, immune tolerance, and reparative potential without genetic reprogramming. The real task is not to make the story louder. It is to make the story clearer, stronger, and more credible.

What this article does not claim

• It does not present Muse cells as a universal answer across every disease state.

• It does not assume all Muse-like or exosome preparations are equivalent.

• It does not treat the 2025 SystemAge case report as definitive proof

The Promise

By the end of this review, one conclusion should be unmistakable: the growing interest in Muse biology is not driven by novelty alone. It is driven by a possibility that matters clinically - an adult-derived, pluripotent-like platform that may unite delivery, tolerance, and repair without laboratory genetic reprogramming. That is the promise. And in regenerative medicine, a serious promise deserves serious evidence.

This review answers four practical questions. What are Muse cells? Why are they different from conventional mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells? What does the human evidence actually show today? And where do Muse-derived exosomes and longevity-oriented signals fit without stretching the science beyond what the literature supports?

What Are Muse Cells?

Before we go further, it is important to build a fence around the idea. "Muse cells" refers to the broader scientific category of multilineage-differentiating stress-enduring cells first described by Professor Mari Dezawa and colleagues in 2010. "Dezawa MuseCells®" and "Dezawa MuseExosomes®" refer to branded products manufactured under licensed methods. That distinction matters. Findings from one manufacturing ecosystem should not be casually transferred to any differently produced cell or exosome preparation. In regenerative medicine, biology matters - but provenance, process, and handling matter too. [1,20-22]

Adult-derived and pluripotent-like

Muse cells were first described as a rare adult-derived subpopulation found within mesenchymal cell populations and other connective tissues. The name itself is a roadmap: multilineage-differentiating stress-enduring. Under the right conditions, Muse cells have been shown to generate cell types across all three germ layers without the laboratory reprogramming required to create iPSCs. That is a major reason the platform has attracted attention. It aims for broad reparative flexibility while remaining rooted in an adult-cell source. [1,2,5,18]

Stress-enduring biology

Muse cells have also shown unusual resilience in low-oxygen, nutrient-depleted, inflamed environments - precisely the settings where damaged tissue needs help most. This stress endurance is not a side feature. It is central to the entire clinical story, because many regenerative platforms weaken in the very biological conditions they are meant to treat. The supplied company materials echo this same theme when they describe Dezawa MuseCells® as stress-enduring in hostile tissue environments. [7,8,20,21]

Naturally occurring with a reassuring safety profile

Unlike embryonic stem cells or laboratory-reprogrammed iPSCs, Muse cells appear to exist naturally in adult tissues. They are not embryonic in origin and do not require genetic reprogramming. Published material describes a safety profile that is encouraging to date, including no tumour formation reported in preclinical or clinical studies of licensed Dezawa MuseCells®. That does not end the need for vigilance, but it is one of the reasons physicians are paying closer attention to this platform. [3,5,20,21]

Why the Field Is Paying Attention

The excitement here is not about sounding futuristic. It is about solving real clinical bottlenecks. Muse cells are drawing attention because they may address three problems regenerative medicine has wrestled with for years: delivery, tolerance, and repair. That idea is worth repeating because if that triad proves durable in wider clinical practice, the field changes. [3,4,18,20]

1) Delivery that may be more purposeful: Conventional MSCs often face a basic translational problem after intravenous administration: a meaningful proportion are thought to become trapped in the lungs, which can limit precise tissue delivery and push their effects toward short-lived paracrine signaling. Muse-cell literature and supplied materials instead describe cells that respond to injury signals and migrate toward damaged tissues. That is one of the clearest fences around the platform. It is not being framed as passive support alone. It is being framed as injury-seeking repair biology. [4,18,20,21]

2) Immune tolerance and allogeneic practicality: Published literature describe an immune profile characterized by human leukocyte antigen-G (HLA-G) positivity, indoleamine 2,3-dioxygenase (IDO) positivity, and human leukocyte antigen-DR (HLA-DR) negativity. In practical terms, that profile helps explain why allogeneic use has been studied without routine immunosuppression or strict human leukocyte antigen matching in the way other cell platforms often require. For clinicians, that is not a small point. It speaks directly to feasibility, simplicity, and scalability. [3,6,20,21]

3) Reparative ambition beyond signaling alone: The Muse-cell thesis is not merely that these cells calm inflammation. It is that they may do two things at once: modulate the local injury environment and participate directly in tissue repair. This is the repeated idea at the heart of the platform: delivery, tolerance, and repair. Not just signalling from a distance. Not just temporary support. The aspiration is structural contribution where damage lives. [1,18,20]

Comparative overview

The table below keeps the core distinctions visible. It compares Muse cells with mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells across the dimensions that matter most clinically.

Table note: Muse-cell properties are drawn from the foundational discovery literature, recent reviews, the uploaded draft article, and the supplied company materials where the article addresses product-specific claims or framing. [1,3-5,18,20,21]

How Muse Cells Are Thought to Work

Distress-signal recognition

When tissue is injured, damaged cells release chemical distress signals into the local environment. Muse cells are thought to respond to that biological context rather than move passively through the body. That responsiveness matters because it helps explain why the platform has been investigated across multiple organ systems instead of being limited to a single tissue niche. [1,18,20]

Active migration

After intravenous administration, Muse cells are described as migrating toward sites of damage rather than distributing randomly. That proposed homing behaviour is one of the strongest conceptual differences between Muse cells and conventional MSC platforms. In plain language: these cells are being studied as if they move toward the problem, not merely around it. [4,18,20,21]

Dual-action repair

Once at the injury site, Muse cells are thought to work through two complementary mechanisms at the same time. They help regulate the inflammatory environment and they may also differentiate into tissue-relevant cells that contribute to repair. That dual-action model is what gives the platform its unusual energy. It suggests a biologic system that may stabilise the crisis while also helping rebuild the structure. [1,6,18]

What the Human Data Shows So Far

One reason Muse cells have moved beyond novelty is simple: published human data already exist. In a field where many platforms never escape preclinical promise, that matters. The strongest controlled signal to date comes from subacute ischemic stroke, where published data reported a 40% response in the treated group versus 10% in placebo. Smaller and earlier studies in acute myocardial infarction, amyotrophic lateral sclerosis (ALS), dystrophic epidermolysis bullosa, and cervical spinal cord injury add to a picture of a platform with real translational momentum - even if the maturity of evidence is not equal across indications. [9-13,18]

That hierarchy matters. Stroke currently carries the strongest controlled proof. The myocardial infarction, ALS, dystrophic epidermolysis bullosa, and spinal cord data are encouraging, but broader validation remains essential. [9-13,18]

Where Muse-Derived Exosomes Fit In

If Muse cells are the repair specialists, Muse-cell-derived exosomes may be the instructions they send ahead. Exosomes are extracellular vesicles that carry proteins, lipids, messenger ribonucleic acid (mRNA), micro-ribonucleic acid (microRNA), and other signaling molecules involved in tissue communication. Their clinical appeal is obvious: if some of the reparative intelligence of the parent cell can be captured in a cell-free format, storage, scale-up, and deployment may eventually become easier. [14,18,21,22]

The honest scientific framing is essential: Muse-derived exosomes are highly promising, but they remain earlier clinically than Muse cells themselves. Today, the stronger evidentiary base sits with the parent Muse-cell literature. Exosomes are the next chapter - exciting, plausible, and increasingly important - but still maturing as a human clinical story. [14,18,21,22]

Skin, Hair, Longevity, and Healthy Ageing

The conversation is now moving beyond acute neurological and cardiovascular repair into the wider territory of longevity medicine, epithelial repair, skin health, hair restoration, and systemic inflammation control. That shift makes sense biologically. A platform that homes to damage, tolerates hostile tissue environments, and may contribute to structural repair has obvious relevance wherever chronic degeneration and low-grade inflammation shape clinical decline. [15-18,21]

Preclinical work supports parts of that interest. Muse cells have been reprogrammed into functional melanocytes, have shown therapeutic effects in corneal scarring models, and have demonstrated specific homing and replacement behaviour in liver-fibrosis models. A 2025 healthy-ageing review by Professor Mari Dezawa further connects Muse biology to the broader question of health span optimisation. Those signals make the platform highly relevant to longevity medicine. They do not remove the need for rigorous clinical validation. [15-18]

A Signal Worth Watching

This is where the 2025 Mathews Journal of Case Reports paper becomes relevant. Khan and Malik reported two anonymized cases assessed with the SystemAge platform, an epigenetic analysis that measures biological ageing across 19 organ systems. One case described a 45-year-old whose overall SystemAge reportedly moved from 53.0 years to 42.1 years after two infusions. The second described a 60-year-old whose SystemAge reportedly shifted from 63.7 years to 52.8 years after one infusion. The paper also reported organ-specific improvements and no adverse events during the follow-up period. [19,21]

Here is the fence around the idea. This was a two-patient case series. Follow-up was short. Results may vary. The paper itself did not isolate Muse cells alone, because the infusion formulation included MUSE cells, MUSE-derived exosomes, and umbilical cord plasma. That means the article is most powerful when used as an illustrative longevity signal. Used that way, it strengthens credibility instead of weakening it. [19,21]

Bottom Line

Muse cells are commanding serious clinical attention because they bring together qualities the field rarely finds in one place: adult-derived biology, pluripotent-like flexibility, stress endurance, injury-responsive homing, immune tolerance, and a safety profile that has been encouraging across published human studies to date. That combination is why the platform keeps resurfacing in discussions about the future of restorative and regenerative medicine. [3,9-13,18,20,21]